

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,294,622 B2
APPLICATION NO. : 10/528640
DATED : November 13, 2007
INVENTOR(S) : Becker et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 152, line 5, claim 1, "R⁹ is phenyl substituted with 0, 1, 2 or 3 R^e," should read
-- R⁹ is phenyl substituted with 0, 1, 2 or 3 R^c; and --.

Column 152, line 11, claim 2, "with 0, 1, 2, or 3 R^o moieties, said ring having 0, 1, or" should read
-- with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, or --.

Column 152, line 36, claim 2, "R^f is NO₂, F, Cl, Br, I, CF₃, CN, C₁-3alkoxy" should read
-- R^f is NO₂, F, Cl, Br, I, CF₃, CN, C₁-3alkyl, or C₁-3alkoxy --.

Column 152, line 39, claim 2, "optionally substituted with 0, 1, or 2 moities, said" should read
-- optionally substituted with 0, 1, or 2 R^f moities, said --.

Column 152, line 40, claim 2, "heterocyclis ring having 0, 1, 2 or 3 nitrogen, oxygen" should read
-- heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen --.

Column 153, line 30, claim 3, "from H, C₁₋₄alkyl, OH, CONR₂, CH₂CONH₂, CO₂H," should read
-- from H, C₁₋₄alkyl, OH, CONH₂, CH₂CONH₂, CO₂H, --.

Column 154, line 63, claim 6, "C₃₋₆alkynyl C₃₋₆cycloalkyl, C₂₋₄alkyNR^aR^b," should read
-- C₃₋₆alkynyl C₃₋₆cycloalkyl, C₂₋₄alkylNR^aR^b --.

Column 155, line 31, claim 7, "from H, C₁₋₄alkyl or C₅₋₆cycloalkyl or R^a and R¹ and" should read
-- from H, C₁₋₄alkyl or C₅₋₆cycloalkyl or R^a and R^b and --.

Column 155, line 38, claim 7, "R² is, at each occurrence independently selected from H," should read
-- R^e is, at each occurrence independently selected from H, --.

Column 160, line 1, claim 24, "(2S)-2-[(cyclohexyloxy)amino]-2-(4-fluorophenyl)-N-" should read
-- (2S)-2-[(cyclohexylacetyl)amino]-2-(4-fluorophenyl)-N- --.

Column 160, line 26, claim 24, "nyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-" should read
-- nyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]N²-[(3,5-difluorophenyl)acetyl]-L- --.


Column 160, line 62, claim 24, "N²-[(2S)-2-hydroxymethyl-1-oxopentyl]-N¹-(2R,3R)-2-" should read
-- N²-[(2S)-2-hydroxy-4-methyl-1-oxopentyl]-N¹-(2R,3R)-2- --.

Column 161, line 13, claim 24, “N²-[(2R,3R)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-2,3,” should read
-- N¹-[(2R,3R)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-2,3, --.

Column 161, line 32, claim 24, “N²-[(3,5-difluorophenyl)acetyl)-4]-N¹-[(2S,3R)-4-oxo-2-” should read
-- N²-[(3,5-difluorophenyl)acetyl]-N¹-[(2S,3R)-4-oxo-2- --.

Signed and Sealed this

Fifth Day of January, 2010

A handwritten signature in black ink that reads "David J. Kappos". The signature is written in a cursive, flowing style with a large, stylized 'D' and 'K'.

David J. Kappos
Director of the United States Patent and Trademark Office